Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
CENTOGENE logo — Empowering precision medicine through advanced diagnosis 

CENTOGENE

Empowering precision medicine through advanced diagnosis 

Founded 2006 Germany Rostock, Germany 476 employees IPO Total: $91.80M Biotechnology, Health Care

General Information

Company Name CENTOGENE
Founded Year 2006
Location Germany Rostock, Germany +7
Founders / Decision Makers
Team member
Employees 476
Industries Biotechnology, Health Care
Funding Stage IPO
Social

Get notified when CENTOGENE moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About CENTOGENE

CENTOGENE, headquartered in Germany, is a pioneer in genetic diagnostics and precision medicine. Dedicated to converting clinical, genetic, and biochemical data into actionable medical solutions, the company champions the early diagnosis and treatment of rare diseases.

Since its founding in 2006, CENTOGENE has expanded its reach to over 100 countries, developing diagnostic capabilities for more than 2,500 rare diseases. Its impressive genetic database encompasses data from over 1,000,000 individuals, solidifying its position as a global leader. The company's dedication to research is evidenced by over 350 scientific publications.

Recently, CENTOGENE received a $20.00M Post IPO Equity investment from Lifera on 01 May 2024, underscoring investor confidence in its strategic direction and innovation capabilities. The company remains a crucial ally for physicians and a sought-after partner for pharmaceutical companies targeting orphan diseases.

Taxonomy: genetic diagnostics, precision medicine, rare diseases, genetic testing, biochemical diagnostics, genetic data interpretation, pharmaceutical partnerships, orphan diseases, next generation sequencing, biomarkers, clinical studies, genetic data analysis, whole exome sequencing, whole genome sequencing, prenatal testing

Services & Products

Whole Genome Sequencing
Multiomic Solutions
Clinical Trial Support
Genetic Testing
Bioinformatics Solutions
Patient Identification
Customized Diagnostics

Target Customers

Physicians Pharmaceutical Companies Researchers Medical Institutions Patients with Rare Diseases

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Equity •••••• 1 •••• •••• 01 May 2024
Post Ipo Convertible •••••• 1 •••• •••• 01 Jun 2023
Post Ipo Debt •••••• 3
Investor Investor Investor
01 Feb 2022
Secondary Market •••••• - 01 Jul 2020
IPO •••••• - 01 Nov 2019

View All 6 Funding Rounds

CENTOGENE Alternatives & Competitors

View All Alternatives
CENTOGENE vs
INTERGEN Genetics and Rare Diseases Diagnosis Research & Application Center
INTERGEN Genetics and Rare Diseases Diagnosis Research & Application Center Turkey

INTERGEN Official Account (INTERGEN Resmi Hesabı)

129 employees
Health Care
Compare CENTOGENE vs INTERGEN Genetics and Rare Diseases Diagnosis Research & Application Center
CENTOGENE vs
3billion
3billion Korea South

Your One Answer Genetic testing for rare diseases made more efficient and more accessible

Series C
68 employees
Health Care, Pharmaceutical
Compare CENTOGENE vs 3billion
CENTOGENE vs
Sapiens Genetics
Sapiens Genetics Turkey

Genetic Diseases Diagnostic Center

34 employees
Also compare with: CENTOGENE vs Dhiti Omics Dhiti Omics View all alternatives

FAQ About CENTOGENE

Empowering precision medicine through advanced diagnosis 
CENTOGENE was founded in 2006.
CENTOGENE is headquartered in Rostock, Germany.
CENTOGENE operates in the following industries: Biotechnology, Health Care.
CENTOGENE has approximately 476 employees.
CENTOGENE has completed 6 funding rounds, raising a total of $91.80M. The latest funding stage is IPO.
CENTOGENE offers: Whole Genome Sequencing, Multiomic Solutions, Clinical Trial Support, Genetic Testing, Bioinformatics Solutions, Patient Identification, Customized Diagnostics.
Top alternatives and competitors to CENTOGENE include INTERGEN Genetics and Rare Diseases Diagnosis Research & Application Center, 3billion, Sapiens Genetics, gMendel, EveryONE Medicines. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CENTOGENE and INTERGEN Genetics and Rare Diseases Diagnosis Research & Application Center are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors CENTOGENE and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy